- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03217864
Implementation of a Return Home With a Hospitalization at Home or With a Home Health Care Provider From the Services of Oncopneumology, Oncology and Hematology of University Hospital of Strasbourg
Implementation of a Return Home With a Hospitalization at Home or With a Home Health Care Provider From the Services of Oncopneumology, Oncology and Hematology of University Hospital of Strasbourg: Observational, Prospective, Monocentric, Non-interventional Study. Advantages, Disadvantages, Limitations
Hospitalization at home is booming. It is designed to meet the demands of patients and their families to continue care at home. It partially solves the problem of the lack of places in the "long-term care" structures and allows to respond to a desire of the health policy to reduce the lengths of stay in the hospital. Hospitalization at home is also an alternative in the management of chronic patients. Nevertheless, at the moment a certain number of requests for hospitalization at home remain unsuccessful or their implementation is complicated. In addition, the number of home health care provider has increased significantly in recent years. According to the federation of home health care provider, the number of beneficiaries increased by 1.7% in 4 years. The home health care provider would support 1,200,000 patients per year.
The objective of the study is to analyze the factors participating in Implementation of a return home with a Hospitalization at home or a home health care provider during a return home project constructed with the patient and his / her relatives from the services of Oncology, oncology, hematology of the University Hospital of Strasbourg.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studieorter
-
-
-
Strasbourg, Frankrike, 67098
- Rekrytering
- Service Soins Palliatifs
-
Huvudutredare:
- Laurent Calvel, MD, PhD
-
Kontakt:
- Marie DEMEUSE, MD
- Telefonnummer: 33 3 88 12 83 39
- E-post: marie.demeuse@chru-strasbourg.fr
-
Kontakt:
- Laurent CALVEL
- Telefonnummer: 33 3 88 12 83 39
- E-post: laurent.calvel@chru-strasbourg.fr
-
Underutredare:
- Marie DEMEUSE, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Patient over 18 years old
- Patient for whom an application for Hospitalization at home or with a home health provider is initiated by the Oncology, Oncology or Hematology Department of the University Hospital of Strasbourg.
Exclusion Criteria:
- Refusal to participate in the study
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Analysis of factors participating in Implementation of a return home with a Hospitalization at home or a home health care provider
Tidsram: 15 days after patient discharge from hospital
|
15 days after patient discharge from hospital
|
Samarbetspartners och utredare
Utredare
- Studierektor: Laurent CALVEL, MD, PhD, University Hospital, Strasbourg, France
- Huvudutredare: Marie DEMEUSE, MD, University Hospital, Strasbourg, France
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- 6843
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .